Skip to content

Study · Animal study (in vivo) · sheep · 1983

1 result

Does DDAVP (1-desamino-8-D-arginine-vasopressin) cross the blood-CSF barrier?

Stegner H, Artman HG, Leake RD, Fisher DA

Neuroendocrinology1 Oct 1983Cited by 24 (Europe PMC)

PMID6633816 (opens in a new tab)DOI10.1159/000123555 (opens in a new tab)PepBankPUB-06633816
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In adult sheep, mean steady-state CSF DDAVP concentration did not differ significantly from zero after intravenous infusion.

    In plain wordsIn sheep, average spinal fluid DDAVP levels did not differ significantly from zero after intravenous infusion.

    Peptide
    Desmopressin
    Outcome
    No significant changeSteady-state CSF DDAVP concentration
    Study

    sheepn = 4

    Adult sheep with chronic cisterna magnum, jugular vein and carotid artery catheters
    Comparator
    Zero
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    12.5-20 ng/kg/min · intravenousAs given in this study (sheep).

    Source sentences

    Summary
    The mean steady-state CSF DDAVP concentration did not vary significantly from zero.
    1 context sentence
    Summary · context
    Plasma and CSF 1-desamino-8-D-arginine-vasopressin (DDAVP) levels were measured by radioimmunoassay following the infusion at constant rates of various amounts of DDAVP (12.5-20 ng/kg/min) into the jugular veins of 4 adult sheep prepared with chronic, indwelling cisterna magnum catheters, as well as…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.